Gemini Bioproducts (US) acquired selected fetal bovine serum (FBS) product rights and inventory from Bio-Techne (US), ensuring continuity of supply for existing customers following Bio-Techne’s decision to discontinue their FBS products. The deal closed on December 3, 2024.
| Acquirer | Gemini Bioproducts (US) |
|---|---|
| Target | Bio-Techne (for selected fetal bovine serum product rights and inventory) (US) |
| Deal value | Undisclosed |
| Type | Acquisition |
| Close date | December 3, 2024 |
| Announcement date | November 25, 2024 |
| Buy-side financial advisors | Agenda Health |
Gemini Bioproducts acquired selected fetal bovine serum (FBS) product rights and inventory from Bio-Techne to ensure uninterrupted supply for customers after Bio-Techne decided to discontinue its FBS line. This acquisition allows GeminiBio to maintain the quality and reliability of these critical cell culture products.
The deal enhances GeminiBio's market position by expanding their offerings in high-quality FBS products, including Optima, Premium Select, and Premium brands. With this move, GeminiBio strengthens its supply chain security and product availability for a diverse customer base ranging from early-stage researchers to commercial biotechs.
Financial Context
Bio-Techne’s decision to discontinue FBS products was driven by strategic realignment in their portfolio. By transferring the rights and inventory to GeminiBio, they ensure that customers have access to these vital cell culture supplies through a reliable supplier.
GeminiBioproducts’ acquisition of Bio-Techne's FBS product lines underscores its commitment to supporting scientific research and biotech development with consistent supply chain management. This strategic move reinforces their role as a key player in the global life sciences industry, particularly in cell culture solutions.
Advisors
Gemini Bioproducts was advised by Agenda Health for this transaction. Financial and legal advisors for Bio-Techne were not disclosed.
The acquisition is expected to bolster GeminiBio's market presence and customer relationships, enhancing their capability to support the life sciences sector with reliable and high-quality FBS products.